Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib in pediatric DIPG and recurrent solid tumors
NCT02644460Phase 1Completed
- Sponsor
- Emory University
- Start
- Feb 2016
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of abemaciclib in diffuse intrinsic pontine glioma (DIPG), brain tumor, solid tumor and 5 more (2 arms), sponsored by Emory University. Primary endpoints: Maximum Tolerated Dose at Week 6, Predose Concentration and 2 more. Started Feb 2016; status: completed.
02
Drugs
abemaciclib
03
Conditions
diffuse intrinsic pontine glioma (DIPG)brain tumorsolid tumorneuroblastomaEwing sarcoma
Beyond the preview
Go deeper on NCT02644460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02644460.